[12] Patent
[11] Patent No.:GC0009247  
[45] Date of Publishing the Grant of the Patent: 31/Dec /2018                56/2018  
Number of the Decision to Grant the Patent:2018/140702
Date of the Decision to Grant the Patent:02/Dec/2018

[21] Application No.:GC 2014-26552

[22] Filing Date:27/2/2014

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
US
1/3/2013
23/7/2013
61/771,655
61/857,636

[72] Inventors:1- BRIZGYS, Gediminas،2- CHOU, Chien-Hung،3- HU, Yunfeng Eric،4- LIU, Qi،5- TSE, Winston C.،6- ZHANG, Jennifer R.،7- CANALES, Eda،8- GRAUPE, Michael،9- LINK, John O.،10- LU, Yafan،11- SAITO, Roland D.،12- SCHROEDER, Scott D.،13- SOMOZA, John R.

[73] Owner: Gilead Sciences, Inc, 333 Lakeside Drive, Foster City, California , USA

[74] Agent: Abu-Gazaleh Intellectual Property L.L.C

  

 

  

[51]IPC:
Int. Cl.: A61K 31/496; A61P 31/14; C07D 401/14, 403/14, 471/04 (2006.01)

[56] Cited Documents:

-WO 2013/006738 A1 (GILEAD SCIENCES INC[US]; BONDY STEVEN S [US]; CANNIZZAROCARINA E [US) 10 January 2013
-WO 2013/006792 A1 (PHARMARESOURCESSHANGHAI CO LTD [CN]; CHEN PING [US]; ZHOUDING [CN];) 10 January 2013
-JEONG J U ET AL: Synthesis of tetrasubstituted pyrazines and pyrazine
N-oxides“,TETRAHEDRON LETTERS, PERGAMON, GB,vo]. 51, no. 6,10 February 2010
 
Examiner: PH. Mohammad S. AlMousa

[54] THERAPEUTIC COMPOUNDS
[57] Abstract: Compounds of formula I: Ior salts thereof are disclosed. Also disclosed are pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.
No. of claims: 34


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.